阿托伐他汀治疗冠心病并高脂血症的效果、安全性及对患者心绞痛平均发作次数的影响分析(1)
【摘要】 目的 研究并探討阿托伐他汀治疗冠心病合并高脂血症的临床效果、安全性及对患者心绞痛平均发作次数的影响。方法 138例冠心病合并高脂血症患者， 在计算机中按照随机数字表法分为对照组和观察组， 每组69例。对照组采用辛伐他汀治疗， 观察组采用阿托伐他汀治疗。比较两组血脂水平、心绞痛平均发作次数、血液流变学指标、不良反应发生率。结果 治疗4、8周后， 两组总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平均较治疗前显著降低， 差异具有统计学意义(P<0.05)；治疗4周
后， 两组患者血脂水平比较差异无统计学意义(P>0.05)；治疗8周后， 观察组患者血脂水平低于对照组， 差异具有统计学意义(P<0.05)。治疗8周后， 两组患者心绞痛平均发作次数均较治疗前显著减少， 且观察组心绞痛平均发作次数(2.18±1.02)次少于对照组的(4.29±1.07)次， 差异具有统计学意义(P<0.05)。治疗8周后， 两组患者血液流变学指标水平均较治疗前显著降低， 且观察组低于对照组， 差异具有统计学意义(P<0.05)。两组不良反应发生率比较， 差异无统计学意义(P>0.05)。结论 在冠心病合并高脂血症患者中， 采用阿托伐他汀治疗兼具显著疗效和可靠安全性， 可起到降低血脂水平、减少心绞痛发作、改善血液流变学等作用。
【关键词】 冠心病；高脂血症；阿托伐他汀；辛伐他汀
DOI：10.14163/j.cnki.11-5547/r.2018.10.050
【Abstract】 Objective To study and discuss the clinical effect and safety of atorvastatin in the treatment of coronary heart disease and hyperlipidemia and its effect on average number of angina pectoris in patients. Methods A total of 138 patients with coronary heart disease and hyperlipidemia were divided by random number table method into control group and observation group， with 69 cases in each group. The control group was treated with simvastatin， and the observation group was treated with atorvastatin. Comparison were made on blood lipid level， average number of angina pectoris， hemorheological indexes， and incidence of adverse reactions between the two groups. Results After 4 and 8 weeks of treatment， both groups had obviously lower total cholesterol， triglycerides and low density lipoprotein cholesterol levels than before treatment， and their difference was statistically significant (P<0.05). After 4 weeks of treatment， both groups had no statistically significant difference in blood lipid level (P>0.05). After 8 weeks of treatment， the observation group had lower blood lipid level than the control group， and their difference was statistically significant (P<0.05). After 8 weeks of treatment， both groups had obviously less average number of angina pectoris than before treatment， and the observation group had less average number of angina pectoris as (2.18±1.02) times than (4.29±1.07) times in the control group. Their difference was statistically significant (P<0.05). After 8 weeks of treatment， both groups had obviously lower hemorheology index level than before treatment， and the observation group was lower than the control group. Their difference was statistically significant (P<0.05). Both groups had no statistically significant difference in incidence of adverse reactions (P>0.05). Conclusion Application of atorvastatin shows remarkable efficacy and reliable safety in patients with coronary heart disease and hyperlipidemia， and it plays a role in lowering blood lipids， reducing angina pectoris and improving hemorheology., 百拇医药(邵素珍)
后， 两组患者血脂水平比较差异无统计学意义(P>0.05)；治疗8周后， 观察组患者血脂水平低于对照组， 差异具有统计学意义(P<0.05)。治疗8周后， 两组患者心绞痛平均发作次数均较治疗前显著减少， 且观察组心绞痛平均发作次数(2.18±1.02)次少于对照组的(4.29±1.07)次， 差异具有统计学意义(P<0.05)。治疗8周后， 两组患者血液流变学指标水平均较治疗前显著降低， 且观察组低于对照组， 差异具有统计学意义(P<0.05)。两组不良反应发生率比较， 差异无统计学意义(P>0.05)。结论 在冠心病合并高脂血症患者中， 采用阿托伐他汀治疗兼具显著疗效和可靠安全性， 可起到降低血脂水平、减少心绞痛发作、改善血液流变学等作用。
【关键词】 冠心病；高脂血症；阿托伐他汀；辛伐他汀
DOI：10.14163/j.cnki.11-5547/r.2018.10.050
【Abstract】 Objective To study and discuss the clinical effect and safety of atorvastatin in the treatment of coronary heart disease and hyperlipidemia and its effect on average number of angina pectoris in patients. Methods A total of 138 patients with coronary heart disease and hyperlipidemia were divided by random number table method into control group and observation group， with 69 cases in each group. The control group was treated with simvastatin， and the observation group was treated with atorvastatin. Comparison were made on blood lipid level， average number of angina pectoris， hemorheological indexes， and incidence of adverse reactions between the two groups. Results After 4 and 8 weeks of treatment， both groups had obviously lower total cholesterol， triglycerides and low density lipoprotein cholesterol levels than before treatment， and their difference was statistically significant (P<0.05). After 4 weeks of treatment， both groups had no statistically significant difference in blood lipid level (P>0.05). After 8 weeks of treatment， the observation group had lower blood lipid level than the control group， and their difference was statistically significant (P<0.05). After 8 weeks of treatment， both groups had obviously less average number of angina pectoris than before treatment， and the observation group had less average number of angina pectoris as (2.18±1.02) times than (4.29±1.07) times in the control group. Their difference was statistically significant (P<0.05). After 8 weeks of treatment， both groups had obviously lower hemorheology index level than before treatment， and the observation group was lower than the control group. Their difference was statistically significant (P<0.05). Both groups had no statistically significant difference in incidence of adverse reactions (P>0.05). Conclusion Application of atorvastatin shows remarkable efficacy and reliable safety in patients with coronary heart disease and hyperlipidemia， and it plays a role in lowering blood lipids， reducing angina pectoris and improving hemorheology., 百拇医药(邵素珍)